MP
PTCT icon

Mangrove Partners’s PTC Therapeutics PTCT Stock Holding History

Mangrove Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-44,000
Closed -$1.88M – 44
2015
Q2 		$2.12M Buy
+44,000
New +$2.57M 0.53% 35

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Mangrove Partners's PTCT Position: Q3 2015 in Review

Mangrove Partners sold out of PTC Therapeutics (PTCT) in Q3 2015, closing a stake of 44,000 shares — an estimated $1.88M sold.

Mangrove Partners first reported a position in PTCT in Q2 2015 and held it in 1 quarter. The position peaked at $2.12M in Q2 2015. 157 funds tracked by Wall St. Rank hold PTCT as of Q3 2015.

  • Mangrove Partners reported no remaining PTC Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Mangrove Partners sold 44,000 PTC Therapeutics shares in Q3 2015, an estimated $1.88M.
  • Mangrove Partners first reported a position in PTC Therapeutics in Q2 2015 and held it in 1 quarter.
  • Mangrove Partners's PTC Therapeutics position peaked at $2.12M in Q2 2015.
  • 157 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2015.

Based on Mangrove Partners's 13F filing for Q3 2015, filed 16 Nov 2015.